艰难梭菌医院感染管理:监测与防控

肖园园 李春辉

肖园园, 李春辉. 艰难梭菌医院感染管理:监测与防控[J]. 疾病监测, 2021, 36(9): 969-974. doi: 10.3784/jbjc.202101020001
引用本文: 肖园园, 李春辉. 艰难梭菌医院感染管理:监测与防控[J]. 疾病监测, 2021, 36(9): 969-974. doi: 10.3784/jbjc.202101020001
Xiao Yuanyuan, Li Chunhui. Management of nosocomial infection of Clostridium difficile: surveillance, prevention and control[J]. Disease Surveillance, 2021, 36(9): 969-974. doi: 10.3784/jbjc.202101020001
Citation: Xiao Yuanyuan, Li Chunhui. Management of nosocomial infection of Clostridium difficile: surveillance, prevention and control[J]. Disease Surveillance, 2021, 36(9): 969-974. doi: 10.3784/jbjc.202101020001

艰难梭菌医院感染管理:监测与防控

doi: 10.3784/jbjc.202101020001
基金项目: 国家自然科学基金(No. 81601803)
详细信息
    作者简介:

    肖园园,女,湖南省衡阳市人,硕士研究生,主要从事艰难梭菌致病机制研究,Email:xiaoyy@csu.edu.cn

    通讯作者:

    李春辉,Tel:0731–89753953,Email:lichunhui@csu.edu.cn

  • 中图分类号: R211; R387

Management of nosocomial infection of Clostridium difficile: surveillance, prevention and control

Funds: This study was supported by the National Natural Science Foundation of China (No. 81601803)
More Information
  • 摘要: 近年来,全球艰难梭菌感染(CDI)的发病率不断上升, 实施有效的监测是控制CDI发生和传播的关键。 CDI监测的内容主要包括病例定义、标准化诊断、病例来源定义、CDI的发病情况以及防控建议。 本综述总结有效的CDI监测的关键组成部分,并提供一些切实可行的防控建议,有助于国家及医院进行标准化监测和防控。
  • 图  1  艰难梭菌感染分类

    注:CDI. 艰难梭菌感染;HA-CDI. 医疗保健相关性CDI;CA-CDI. 社区相关性CDI

    Figure  1.  Classification of Clostridium difficile infection

    表  1  艰难梭菌感染的实验室检测方法比较

    Table  1.   Comparison of CDI laboratory test methods

    检测分类方法检测物质优点缺点参考文献
    菌株检测细菌培养艰难梭菌可获得菌株,敏感性高检测需1~3 d,不能区别非产毒菌株3, 11
    谷氨酸脱氢酶检测艰难梭菌快速简便,阴性预测值高特异性差,不能区别非产毒菌株11, 14
    毒素检测细胞毒性试验毒素B实验室诊断艰难梭菌的金标准,敏感性高,特异性强检测需1~3 d,技术要求高3, 11, 1417
    产毒素艰难梭菌培养产毒素艰难梭菌实验室诊断艰难梭菌的参考方法,敏感性高,特异性强检测需3~5 d,技术要求高11, 16
    A/B EIA毒素A/B快速简便,特异性高敏感性低,假阴性率高11, 14
    毒素基因检测核酸扩增试验毒素基因快速,敏感性、特异性均高成本高11, 15
      注:EIA. 酶免疫分析;A/B EIA. 采用酶免疫分析方法检测艰难梭菌的A、B两种毒素
    下载: 导出CSV
  • [1] Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and Meta-analysis[J]. Infect Control Hosp Epidemiol, 2015, 36(4): 452–460. DOI:  10.1017/ice.2014.88.
    [2] Lee HY, Hsiao HL, Chia CY, et al. Risk factors and outcomes of Clostridium difficile infection in hospitalized patients[J]. Biomed J, 2019, 42(2): 99–106. DOI:  10.1016/j.bj.2018.12.002.
    [3] 季欣欣, 孟秀娟. 艰难梭菌感染的诊断及治疗研究进展[J]. 中国感染控制杂志,2019,18(6):600–606. DOI:10.12138/j.issn.1671−9638.20195349.

    Ji XX, Meng XJ. Research progress in diagnosis and treatment of Clostridium difficile infection[J]. Chin J Infect Control, 2019, 18(6): 600–606. DOI: 10.12138/j.issn.1671−9638.20195349.
    [4] Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections[J]. N Engl J Med, 2014, 370(13): 1198–1208. DOI:  10.1056/NEJMoa1306801.
    [5] Giancola SE, Williams II RJ, Gentry CA. Prevalence of the Clostridium difficile BI/NAP1/027 strain across the United States Veterans Health Administration[J]. Clin Microbiol Infect, 2018, 24(8): 877–881. DOI:  10.1016/j.cmi.2017.11.011.
    [6] Oñate-Gutiérrez JM, Segura J, Correa A, et al. Clostridium difficile infection: description of NAP1/027 and non NAP1/027 strains in a high complexity center in Cali, Colombia, 2012–2015[J]. Biomedica, 2019, 39 Suppl 1: 63–70. DOI:  10.7705/biomedica.v39i2.3950.
    [7] Rodriguez C, Fernandez J, van Broeck J, et al. Clostridium difficile presence in Spanish and Belgian hospitals[J]. Microb Pathog, 2016, 100: 141–148. DOI:  10.1016/j.micpath.2016.09.006.
    [8] Li CH, Duan JP, Liu SD, et al. Assessing the risk and disease burden of Clostridium difficile infection among patients with hospital-acquired pneumonia at a university hospital in central China[J]. Infection, 2017, 45(5): 621–628. DOI: 10.1007/s15010−017−1024−1.
    [9] 谢和宾, 曾鸿, 尹柯, 等. 我国住院腹泻患者艰难梭菌感染率的荟萃分析[J]. 中华医院感染学杂志,2017,27(5):961–964. DOI:10.11816/cn.ni.2016−163019.

    Xie HB, Zeng H, Yin K, et al. Prevalence rate of Clostridium difficile infection in hospitalized patients with diarrhea in China: a meta-analysis[J]. Chin J Nosocomiol, 2017, 27(5): 961–964. DOI: 10.11816/cn.ni.2016−163019.
    [10] Kola A, Wiuff C, Akerlund T, et al. Survey of Clostridium difficile infection surveillance systems in Europe, 2011[J]. Euro Surveill, 2016, 21(29): 30291. DOI: 10.2807/1560−7917.ES.2016.21.29.30291.
    [11] 程敬伟, 刘文恩, 马小军, 等. 中国成人艰难梭菌感染诊断和治疗专家共识[J]. 协和医学杂志, 2017, 8增刊1: 131–138. DOI:  10.3969/j.issn.1674-9081.2017.03.010.

    Cheng JW, Liu WE, Ma XJ, et al. Consensus among experts on diagnosis and treatment of Clostridium difficile infection in Chinese adults[J]. Med J Peking Union Med College Hosp, 2017, 8 Suppl 1: 131–138. DOI:  10.3969/j.issn.1674-9081.2017.03.010.
    [12] Krutova M, Kinross P, Barbut F, et al. How to: Surveillance of Clostridium difficile infections[J]. Microbiol Infect, 2018, 24(5): 469–475. DOI:  10.1016/j.cmi.2017.12.008.
    [13] 中华预防医学会医院感染控制分会. 中国艰难梭菌医院感染预防与控制指南[J]. 中华医院感染学杂志,2018,28(23):3674–3680. DOI:10.11816/cn.ni.2018−183451.

    Nosocomial Infection Control Branch of Chinese Preventive Medical Association. Guidelines for prevention and control of nosocomial Clostridium difficile infection in China[J]. Chin J Nosocomiol, 2018, 28(23): 3674–3680. DOI: 10.11816/cn.ni.2018−183451.
    [14] Crobach MJT, Planche T, Eckert C, et al. European society of clinical microbiology and infectious diseases: update of the diagnostic guidance document for Clostridium difficile infection[J]. Clin Microbiol Infect, 2016, 22 Suppl 4: S63–S81. DOI:  10.1016/j.cmi.2016.03.010.
    [15] Rao K, Malani PN. Diagnosis and treatment of Clostridioides (Clostridium) difficile infection in adults in 2020[J]. JAMA, 2020, 323(14): 1403–1404. DOI:  10.1001/jama.2019.3849.
    [16] 中华预防医学会. 艰难梭菌感染诊断(T/CPMA 008–2020)[J]. 中华医院感染学杂志,2021,31(2):315–320. DOI:10.11816/cn.ni.2020−202724.

    Chinese Preventive Medicine Association. Diagnosis of Clostridium difficile infection (T/CPMA 008–2020)[J]. Chin J Nosocomiol, 2021, 31(2): 315–320. DOI: 10.11816/cn.ni.2020−202724.
    [17] 刘昊, 徐修礼, 张瑞雪. 艰难梭菌感染实验室检测方法进展[J]. 中国感染控制杂志,2017,16(1):89–93. DOI:10.3969/j.issn.1671−9638.2017.01.022.

    Liu H, Xu XL, Zhang RX. Advances in laboratory testing for Clostridium difficile infection[J]. Chin J Infect Control, 2017, 16(1): 89–93. DOI: 10.3969/j.issn.1671−9638.2017.01.022.
    [18] Ma GK, Brensinger CM, Wu QF, et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study[J]. Ann Intern Med, 2017, 167(3): 152–158. DOI: 10.7326/M16−2733.
    [19] Tang DM, Urrunaga NH, von Rosenvinge EC. Pseudomembranous colitis: not always Clostridium difficile[J]. Cleve Clin J Med, 2016, 83(5): 361–366. DOI:  10.3949/ccjm.83a.14183.
    [20] Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States[J]. N Engl J Med, 2015, 372(9): 825–834. DOI:  10.1056/NEJMoa1408913.
    [21] Lin HJ, Hung YP, Liu HC, et al. Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization[J]. J Microbiol Immunol Infect, 2015, 48(2): 183–189. DOI:  10.1016/j.jmii.2013.08.003.
    [22] Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)[J]. Infect Control Hosp Epidemiol, 2010, 31(5): 431–455. DOI:  10.1086/651706.
    [23] Ofori E, Ramai D, Dhawan M, et al. Community-acquired Clostridium difficile: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies[J]. J Hosp Infect, 2018, 99(4): 436–442. DOI:  10.1016/j.jhin.2018.01.015.
    [24] Brown KA, Khanafer N, Daneman N, et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection[J]. Antimicrob Agents Chemother, 2013, 57(5): 2326–2332. DOI: 10.1128/AAC.02176−12.
    [25] Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and Meta-analysis[J]. J Antimicrob Chemother, 2014, 69(4): 881–891. DOI:  10.1093/jac/dkt477.
    [26] Pakyz AL, Jawahar R, Wang Q, et al. Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multievel model case-control study among 64 US academic medical centres[J]. J Antimicrob Chemother, 2014, 69(4): 1127–1131. DOI:  10.1093/jac/dkt489.
    [27] Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection[J]. J Hosp Infect, 2008, 70(4): 298–304. DOI:  10.1016/j.jhin.2008.08.012.
    [28] Tariq R, Singh S, Gupta A, et al. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis[J]. JAMA Intern Med, 2017, 177(6): 784–791. DOI:  10.1001/jamainternmed.2017.0212.
    [29] Leffler DA, Lamont JT. Clostridium difficile infection[J]. N Engl J Med, 2015, 372(16): 1539–1548. DOI:  10.1056/NEJMra1403772.
    [30] Zhao S, Ghose-Paul C, Zhang KS, et al. Immune-based treatment and prevention of Clostridium difficile infection[J]. Hum Vaccin Immunother, 2014, 10(12): 3522–3530. DOI:  10.4161/21645515.2014.980193.
    [31] McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)[J]. Clin Infect Dis, 2018, 66(7): e1–48. DOI:  10.1093/cid/cix1085.
    [32] European Centre for Disease Prevention and Control. European surveillance of Clostridioides (Clostridium) difficile infections - surveillance protocol version 2.4[EB/OL]. (2019–10–17)[2021–03–09]. https://www.ecdc.europa.eu/en/publications-data/european-surveillance-clostridium-difficile-infections-surveillance-protocol-2.
    [33] Centers for Disease Control and Prevention of America. Multidrug-resistant organism and Clostridium difficile infection module[EB/OL]. (2021–01)[2021–03–09]. https://www.cdc.gov/nhsn/psc/cdiff/index.html.
    [34] Tschudin-Sutter S, Kuijper EJ, Durovic A, et al. Guidance document for prevention of Clostridium difficile infection in acute healthcare settings[J]. Clin Microbiol Infect, 2018, 24(10): 1051–1054. DOI:  10.1016/j.cmi.2018.02.020.
    [35] 杜明梅, 刘运喜, 索继江, 等. 医院感染暴发实时监测预警的实现及临床应用[J]. 中华医院感染学杂志,2012,22(14):3104–3106.

    Du MM, Liu YX, Suo JJ, et al. Real-time monitoring and early warning of nosocomial infection outbreaks and its clinical application[J]. Chin J Nosocomiol, 2012, 22(14): 3104–3106.
    [36] Dubberke ER, Carling P, Carrico R, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update[J]. Infect Control Hosp Epidemiol, 2014, 35(6): 628–645. DOI:  10.1086/676023.
    [37] Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec[J]. CMAJ, 2005, 173(9): 1037–1042. DOI:  10.1503/cmaj.050978.
    [38] Vonberg RP, Kuijper EJ, Wilcox MH, et al. Infection control measures to limit the spread of Clostridium difficile[J]. Clin Microbiol Infect, 2008, 14 Suppl 5: 2–20. DOI: 10.1111/j.1469−0691.2008.01992.x.
    [39] Barlam TF, Cosgrove SE, Abbo LM, et al. Executive summary: implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America[J]. Clin Infect Dis, 2016, 62(10): 1197–1202. DOI:  10.1093/cid/ciw217.
    [40] Goldstein EJC, Johnson S, Maziade PJ, et al. Pathway to prevention of nosocomial Clostridium difficile infection[J]. Clin Infect Dis, 2015, 60 Suppl 2: S148–158. DOI:  10.1093/cid/civ142.
    [41] Balsells E, Filipescu T, Kyaw MH, et al. Infection prevention and control of Clostridium difficile: a global review of guidelines, strategies, and recommendations[J]. J Glob Health, 2016, 6(2): 020410. DOI:  10.7189/jogh.06.020410.
    [42] Sethi AK, Al-Nassir WN, Nerandzic MM, et al. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection[J]. Infect Control Hosp Epidemiol, 2010, 31(1): 21–27. DOI:  10.1086/649016.
    [43] Guerrero DM, Nerandzic MM, Jury LA, et al. Acquisition of spores on gloved hands after contact with the skin of patients with Clostridium difficile infection and with environmental surfaces in their rooms[J]. Am J Infect Control, 2012, 40(6): 556–558. DOI:  10.1016/j.ajic.2011.08.002.
    [44] Stiefel U, Cadnum JL, Eckstein BC, et al. Contamination of hands with methicillin-resistant Staphylococcus aureus after contact with environmental surfaces and after contact with the skin of colonized patients[J]. Infect Control Hosp Epidemiol, 2011, 32(2): 185–187. DOI:  10.1086/657944.
    [45] Jabbar U, Leischner J, Kasper D, et al. Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands[J]. Infect Control Hosp Epidemiol, 2010, 31(6): 565–570. DOI:  10.1086/652772.
    [46] Oughton MT, Loo VG, Dendukuri N, et al. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile[J]. Infect Control Hosp Epidemiol, 2009, 30(10): 939–944. DOI:  10.1086/605322.
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  164
  • HTML全文浏览量:  91
  • PDF下载量:  34
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-01-02
  • 网络出版日期:  2021-07-28
  • 刊出日期:  2021-09-30

目录

    /

    返回文章
    返回

    在线交流

    防诈骗公告

    近期有不法分子以本刊编辑身份添加作者微信,请务必提高警惕!本刊关于稿件的一切事项通知均采用编辑部唯一邮箱(jbjc@icdc.cn)和座机(010-58900732)联系作者,且在录用稿件后仅收取版面费,无其他任何名目费用(如审稿费和加急费等),非编辑部邮箱发送的本刊收费用通知等均为诈骗,不要随意汇入款项!如有可疑及时致电编辑部核实确认!